MedTrace Logo

Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis

NCT05029830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-02-06

No results posted yet for this study

Summary

1. use QoL assessments to check whether interventions have been as effective from the patient's point of view as from the clinician's, and to determine whether further action is required . Knowledge of which factors are determinants of QoL in patients with MS would assist clinicians in choosing the most appropriate interventions. Several determinants of QoL have been identified with varying strengths of association and include both disease-related variables (disability status ,disease duration ,fatigue ,depression ,cognition , sociodemographic variables (age and sex ,level of education, and marital status . A number of these factors might be amenable to treatment intervention, which might be expected to improve QoL: fatigue , depression , and cognition
2. To study effect of psychiatric comorbidity on the disease activity by using clinical, laboratory and psychiometric tools.

Conditions

  • Multiple Sclerosis Acute and Progressive

Interventions

COMBINATION_PRODUCT

investigations like MRI..

• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Shady safwat, lecturer · Assiut University

  • gellan karm, lecturer · Assiut University

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-01
Completion
2022-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029830 on ClinicalTrials.gov